Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland

BackgroundPatients with mental disorders are at increased risk of hepatitis C virus (HCV) infection, yet the prevalence of HCV among patients in Polish psychiatric ward remains unknown.MethodsA cross-sectional survey was conducted in Poland from 2021 to 2023 in psychiatric wards. Adults recently hospitalized with at least one current mental health condition were eligible and 12–897 individuals were tested for anti HCV antibodies. Patients with confirmed active HCV infection (subsequent nucleic acid testing) were offered treatment.ResultsOf the 12,897 individuals who constituted the sample, 64% were male, and the median age was 45 years (interquartile range: 35–58 years). Among those subjects, 226 patients (representing 1.8% of the total) exhibited a positive HCV antibody test result, and 172 of these patients had active HCV infection (the prevalence of 1.3%). Multivariate analysis identified five risk factors for HCV infection within the investigated population: intravenous drug use (odds ratio [OR] = 9.40; 95% confidence interval [CI]: 6.12–14.44; p<0.001), diagnosed and treated liver disease (OR = 6.17; 95% CI: 4.10–9.26; p < 0.001); blood transfusions prior to 1992 (OR = 2.61; 95% CI: 1.29–5.28; p=0.008), diagnosis of mental and behavioral disorders due to psychoactive substance abuse (OR = 1.97; 95% CI: 1.34–2.91; p=0.001) and previous incarceration (OR = 1.62; 95% CI: 1.08–2.43, p=0.018).ConclusionsHigh prevalence of HCV infection in patients with mental health disorders and specifically in patients who used intravenous drugs suggests the importance of screening for HCV in this vulnerable population.

Family caregivers’ involvement in home-based recovery for patients with schizophrenia: a qualitative study in Beijing, China

BackgroundFamily caregivers play critical roles in supporting the home-based recovery of patients with schizophrenia, but they often encounter substantial challenges and receive insufficient systemic support. Understanding caregivers’ involvement in home-based recovery is essential for aligning community mental health services with families’ capacities and needs. This study aimed to explore family caregivers’ involvement and adaptive processes in supporting home-based recovery of patients with schizophrenia in China.MethodsA qualitative study using interpretative phenomenological analysis was conducted through semi-structured interviews. Family caregivers were purposively recruited from four community health service centers (CHSCs) across urban and rural areas of Beijing. All interviews were audio-recorded, transcribed verbatim, anonymized, and analyzed iteratively to identify themes and subthemes.ResultsA total of 20 family caregivers were recruited, including 11 from two urban districts and 9 from a rural district in Beijing. Five themes were identified: Caregivers’ redefinition of recovery as stability rather than cure; Routine recovery involvement in medication management and symptom monitoring; Experienced tensions between the patient’s independence and relapse prevention; Bearing family obligation and personal strain in sustained caregiving involvement; and Uncertainty in sustaining caregiving and the patients’ future stability. Caregivers reported persistent challenges in supporting patients’ independent living, participation in family activities, communication, and social interaction.ConclusionFamily caregivers gradually develop their capacity to support home-based recovery, but continue to encounter complex challenges while receiving limited support from CHSCs. Strengthening recovery-oriented family support within community mental health services, particularly through accessible psychoeducation and rehabilitation guidance, may enhance caregivers’ capacity to support patients’ independence and social participation, thereby promoting sustainable home-based care and long-term functional recovery.

Case Report: A novel de novo heterozygous truncating mutation in MED12L identified in a Chinese autistic boy

BackgroundAutism spectrum disorder (ASD) is a highly heterogeneous neurodevelopmental disorder. A previous study by Nizon et al. indicated that some children with intellectual disability (ID) carrying de novo MED12L mutations exhibited mild to moderate autistic features. However, the relationship between MED12L and ASD remains unclear.Case presentationHere we reported a male child with severe autistic features carrying a novel de novo heterozygous truncating mutation of MED12L (NM_053002.5:c.586C>T, p.(Arg196Ter)). He was diagnosed with ASD according to ICD-11 and DSM-5 criteria. Clinical examination indicated that this child exhibited severe autistic features and several dysmorphic features, including a flat nasal bridge, bulbous nasal tip, thin upper lip, and triangular face. Magnetic resonance imaging (MRI) of the brain revealed an enlarged perivascular space in the right temporal lobe.ConclusionThis case demonstrates that this de novo heterozygous truncating mutation in MED12L may be involved in the development of ASD, and haploinsufficiency of MED12L may be associated with severe autistic features. Obvious clinical manifestations and dysmorphic features in this child with a truncating mutation in MED12L expand the phenotypic spectrum of MED12L-related cases and warrant further functional studies to elucidate the relationship between MED12L and ASD.

Intracranial hypertension after MECT: successful transition to rTMS for refractory auditory hallucinations: a case report

A 21-year-old female patient with schizophrenia, whose primary symptom was refractory auditory hallucinations, developed intracranial hypertension syndrome following her first session of modified electroconvulsive therapy (MECT), presenting with severe headache, projectile vomiting, diplopia and meningeal signs. She subsequently received 1 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left temporo-parietal cortex with each session delivering 1,500 pulses at 74% of the resting motor threshold. Her auditory hallucinations diminished markedly 3 days after completing rTMS and resolved completely 1 week later, accompanied by improved social functioning. No recurrence was observed during 3 weeks of follow-up. This case primarily demonstrates that rTMS may represent a safe and effective alternative for patients with refractory auditory hallucinations who are intolerant to MECT. It serves as a clinical reminder to maintain vigilance for elevated intracranial pressure following MECT, particularly in patients with a history of migraine.

An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

Nature Medicine, Published online: 13 July 2026; doi:10.1038/s41591-026-04518-z

In a phase 1 trial, treatment with the antibody−drug conjugate DYP688, targeting PMEL and delivering a Gq/11 inhibitor, in patients with GNAQ/GNA11-mutant metastatic uveal melanoma or other GNAQ/GNA11-mutant melanomas, showed acceptable safety and encouraging preliminary efficacy, with supporting biomarker data for proof of mechanism.

Genetic Map Opens Door to Development of New Therapies to Reverse Bone Loss

An international team of scientists report that they have successfully mapped the cells and genes that regulate bone formation and loss and discovered the critical role that blood vessel cells play in bone health. By combining genomic sequencing with data from half a million individuals, the research team identified hundreds of previously unknown genes that govern bone health and revealed cells surrounding blood vessels as one of the drivers of bone repair.

The study “Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease” is published in Nature Genetics. The team says its findings fundamentally enhance our understanding of skeletal disease. It is hoped the discovery will enable the development of new therapies to rebuild lost bone, offering hope to almost half of all individuals over 50 living with rare and common skeletal conditions such as osteoporosis, osteoarthritis and osteogenesis imperfecta, as well as those with rare bone disorders and cancers that spread to bone.

“Most people don’t realize that bones are constantly changing; the human body replaces its skeleton every 10 years or so,” said Peter Croucher, PhD, professor at the Garvan Institute of Medical Research in Australia. “This is a hugely important process, but until now we’ve had a limited understanding of the cells and mechanisms that control this turnover of bone. “Most of the drugs now available focus only on halting bone disease, rather than rebuilding lost bone, which is really important for reversing damage.”

Detailed map of cells and genes that regulate bone health

The team used single-cell RNA sequencing to measure which genes are switched on within individual cells found in bone, focusing on the interface between the hard bone and bone marrow which is the key site for the formation and breakdown of bone.

The Institute’s Ryan Chai, PhD, pointed out that the team’s analysis found 34 different groups of cells and defined the genes that are active in each of these cell types. “To our surprise, more than half of the genes identified have never before been shown to play a role in maintaining bone health, which is a significant finding,” he added.

Ryan Chai, PhD, and Peter Croucher, PhD, from the Garvan Institute of Medical Research. [Garvan Institute]
Ryan Chai, PhD, and Peter Croucher, PhD, from the Garvan Institute of Medical Research [Garvan Institute]

The team used its map to identify cells involved in rare and common skeletal diseases, including osteogenesis imperfecta and osteoporosis. For the latter, the researchers analyzed the UK Biobank, one of the world’s biggest and most comprehensive collections of biological samples.

By analyzing genetic and bone density data from half a million people participating in the UK Biobank, the team was able to pinpoint exactly which cells drive skeletal disease, according to John Kemp, PhD, associate professor from Mater Research.

“These include cells known to regulate bone formation and bone loss, as well as blood vessel cells that, until now, have had underappreciated roles in bone health,” he said.

Croucher explained that the research uncovered new therapeutic opportunities against not only bone disease, but also cancer. “Bone is the main hiding place for dormant cancer cells and a common site of relapse, so identifying the cells and genes that drive bone turnover also opens new opportunities to prevent cancer metastasis,” he said.

The team is now further investigating the roles of newly discovered bone-regulating cells and genes in the hope of developing new medicines against these targets. Its data has been made accessible to medical researchers worldwide through an open access platform.

 

 

The post Genetic Map Opens Door to Development of New Therapies to Reverse Bone Loss appeared first on GEN – Genetic Engineering and Biotechnology News.

Caregivers brace for pay cuts, and maybe homelessness 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. In case you missed it, my pal Bob Herman got the Joe Kernan treatment on CNBC’s “Squawk Box” on Friday, where he discussed his excellent new series “Out of Pocket, Out of Reach.” Kernan got in a lot of digs at Democrats and Obamacare, but Bob kept his comments apolitical. A true professional! 

Read the rest…

Opinion: Is there a doctor on board? Yes, and airlines depend on it

On three of my last seven flights, a request came over the cabin speakers: “Is there a doctor on board?” Like many physicians, I responded automatically.

What struck me afterward was not the frequency of those requests but how unremarkable the whole process seemed — to the crew, to other passengers, and, eventually, to me. None of the patients were in cardiac arrest. The complaints were the kind that fill any urgent care waiting room on a Tuesday afternoon: dizziness, nausea, feeling faint, generalized malaise.

Read the rest…

STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come

LONDON — When researchers started planning a pancreatic cancer conference here, the aim was to simply offer a counterpart to a regular U.S. meeting, where international scientists and doctors could discuss the latest developments in the specialty. 

Then came the biggest shake-up in pancreatic cancer care in decades. 

“It’s one of those moments,” Talia Golan, an oncologist at Israel’s Sheba Medical Center, said on a panel that conference organizers hastily added to the schedule centered on a new pancreatic cancer drug. She likened the medicine’s recent clinical trial performance to other milestones in cancer treatment such as the arrival of the first checkpoint inhibitors. 

Continue to STAT+ to read the full story…